Process Analytical Technology
for in line bioproduction monitoring

Genomic companion for biologics

The bioproduction challenge

Limited capacity and performance

By 2024, forecasts indicate that 50% of the top 100 most prescribed drugs will be biologics, accounting for 32% of the overall pharmaceutical market. Therapeutic progress and patient access to new biotherapies now rely on bioproduction capacity and performance.

New guidance? new tool

In 2004: the launch of FDA’s guidance on process analytical technology (PAT) set the regulatory framework for biopharmaceutical processes. It covers increasing express system and process understanding, process robustness, improving yields by way of less rejections.


GenSensor was founded with a vision to become a game changer in the field of genomic based in-line bioproduction monitoring.

Our company combines the development of a robotic device with an advanced analytics software to monitor, characterize, optimize your bioproduction of ATMP and vaccines.